Compugen Ltd. is a clinical-stage therapeutic discovery and development company nearing breakeven. Analysts predict the company may become profitable by 2025, with a 50% year-on-year growth rate. Despite being a loss-making biotech, Compugen has no debt, reducing investment risks.